Loading…
← CockpitCompetitor Analysis › CURA.TO Curaleaf Holdings, Inc.Open in the cockpit ↗

Curaleaf Holdings, Inc.CURA.TOCompetitor analysis, valuation and peers

Canada · CAD·Consumer Staples›Agricultural Commodities/Milling

One of the largest US multi-state cannabis operators, growing, processing and retailing cannabis products across many US states.

≈ A leading US cannabis MSO (multi-state operator)Momentum neutral 44
Mkt cap
$2.10B
US dollars, full cap
Free float
73%
of shares outstanding
$/day
$2.38M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-9.2 pp
WACC 9.6%
Hurdle
n/a
no reverse DCF
Next earnings
106 days
4 Mar 2027
Close · CADC$11.35
1D-0.5%
1W-10.6%
1M+2.5%
3M-16.4%
6M-17.0%
YTD+10.9%
1Y+33.7%
ATR %6.6%
52w lowhigh45.8% off high

What Curaleaf does

One of the largest US multi-state cannabis operators, growing, processing and retailing cannabis products across many US states.

Sells through its own dispensaries, where it keeps the retail margin, and wholesales what it grows to other stores, state by state under separate licences. Rules and tax treatment differ by state, so results depend on each market's licence count and pricing.

In one line: A leading US cannabis MSO (multi-state operator).

Products and services

  • Cannabis cultivation/processing
  • Retail dispensaries
  • Branded cannabis products
  • International (European) cannabis operations

Customers

  • Medical and adult-use cannabis consumers (US)

Where it sits in the supply chain

  • Cannabis
  • Cultivation/processing
  • Retail dispensaries

What could go right

  • US cannabis rescheduling/legalisation progress
  • Store network/market expansion

What could go wrong

  • Federal illegality limits banking/tax treatment
  • State-level price compression/oversupply

Moat: narrow (scale, brand, regulatory licence). State cannabis licences and multi-state cultivation/retail scale are barriers, though the market remains fragmented and competitive.

Headquarters: Wakefield, Massachusetts, US · Founded: 2010 · Employees: 5,554

Named competitors

  • Trulieve Cannabis TRLV
  • Green Thumb Industries private or unlisted
  • Verano Holdings private or unlisted
  • Cresco Labs private or unlisted
  • TerrAscend private or unlisted
  • Glass House Brands private or unlisted

Curaleaf at a glance

Size Curaleaf (CURA.TO) is a Canada Consumer Staples company (Agricultural Commodities/Milling) with a market value of $2.10B, the 174th largest of 405 Canada companies the cockpit tracks. Shares closed at C$11.35 on 18 Nov 2026.

Performance Over six months the shares fell 17.0%, against 0.0% for the median peer and +1.1% for the Canada market (cap-weighted) — 6th lowest of 21 in its peer set.

Growth Revenue grew 5.0% over the last twelve months (peer median +2.9%); the operating margin is 0.8% (peer median 5.9%).

Valuation It trades at 2.4× enterprise value to sales against a peer median of 1.5× (7th most expensive of 21).

Capital Return on invested capital runs 9.2 points below its cost of capital (9.6% WACC).

Next results Next results expected around 4 Mar 2027 (exchange calendar; dates can move).

Relative performance

8010012021 May 202621 Aug 202618 Nov 2026Peer median 102CURA.TO 81
Six months, rebased to 100: Curaleaf against the median of its 20 peers (local-currency closes).

Curaleaf financials

Reported figures in CAD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueC$1.87BC$1.77BC$1.83BC$1.82BC$1.66B
Revenue growth—-3%+1%+9%—
Gross profitC$722MC$684MC$642MC$645MC$668M
EBITDAC$315MC$337MC$374MC$344MC$300M
Net income-C$30.1M-C$382M-C$326M-C$380M-C$482M
Free cash flowC$67.0MC$104MC$97.5MC$13.2M-C$115M
Capital expenditureC$96.9MC$90.3MC$133MC$94.9MC$175M
Total debtC$1.61BC$1.42BC$1.53BC$1.45BC$1.55B

Quarterly statements and history in the cockpit →

Curaleaf competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-20%0%+20%-10%0%+10%1229000833BFGTRLV2607BIOMARAWLGNS002385UIE605296002100E5H000998P8ZLTFOODS3007610000611117CURA.TO6-month return →1-month return →
Up and to the right = strong over both horizons. Curaleaf is the large dot.

Fundamentals: revenue growth against valuation

-10%0%+10%+20%+30%1×2×3×1229000833BFGTRLV2607BIOMARAWLGNS002385UIE605296002100E5H000998601952P8ZLTFOODS3007610000611117CURA.TORevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Curaleaf is the large dot.

Curaleaf competitors and peer comparison

Head to head with its named competitors (CURA.TO vs TRLV)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Curaleaf CURA.TO$2.10B-17%+5%1%2.4×n/a
Trulieve Cannabis TRLV$1.93B+25%-9%15%2.0×11.2%

How Curaleaf compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Curaleaf against its 20 peers (data as of 18 Nov 2026)
MeasureCURA.TOPeer medianRank in peer set
1-month return+2.5%-3.6%6th highest of 21
6-month return-17.0%0.0%6th lowest of 21
Distance from 52-week high-45.8%-23.7%5th lowest of 21
Revenue growth (TTM)+5.0%+2.9%10th highest of 21
Operating margin0.8%5.9%6th lowest of 21
EV / Sales2.4×1.5×7th most expensive of 21
ROIC minus cost of capital-9.2 pp-1.6 pp3rd lowest of 21
EV / EBITDA14.2×10.3×2nd most expensive of 9
Net debt / EBITDA4.6×1.8×2nd most indebted of 11

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Curaleaf CURA.TOCanada$2.10B-17%+5%1%2.4×n/an/a
Lien Hwa Industrial 1229.TWTaiwan$2.20B+2%+1%19%8.0×12.0%+7.3%
Guangxi Yuegui Guangye 000833.SZChina$1.96B-46%+67%30%2.7×0.4%-0.9%
B.F BFG.MIItaly$2.26B+59%+30%-2%1.6×n/an/a
Trulieve Cannabis TRLVUnited States$1.93B+25%-9%15%2.0×11.2%+17.8%
Fuji Oil 2607.TJapan$2.30B+24%+4%5%0.8×0.4%+16.2%
BioMar Group A/S BIOMAR.CODenmark$1.85B-31%0%6%0.9×-1.2%-0.5%
AWL Agri Business AWL.NSIndia$2.38B-15%+18%2%0.4×13.9%+15.0%
Genus GNS.LUnited Kingdom$1.81B-13%-2%13%2.2×16.1%+2.8%
Beijing Dbn Technology 002385.SZChina$1.78B-22%-1%-6%0.8×n/an/a
Uie UIE.CODenmark$1.71B+8%+11%40%3.0×-15.2%+13.1%
Yunnan Shennong Agricultural Industry 605296.SSChina$2.57B+10%+2%-19%3.4×n/an/a
Tecon Biology 002100.SZChina$1.69B+14%-8%-5%1.1×n/an/a
Golden Agri-Resources E5H.SISingapore$2.66B-2%+9%6%0.4×-13.8%+11.6%
Yuan Longping High-Tech Agriculture 000998.SZChina$1.65B-14%-5%5%2.7×n/an/a
Jiangsu Provincial Agricultural Reclamation & Dev 601952.SSChina$1.63B-13%-5%4%1.3×-2.9%+3.2%
Bumitama Agri P8Z.SISingapore$1.61B-28%+9%25%1.3×-16.8%+12.9%
LT Foods LTFOODS.NSIndia$1.56B+2%+24%8%1.2×25.8%+18.2%
Jiangsu Lihua Animal Husbandry 300761.SZChina$2.84B+2%+7%3%1.1×3.6%+16.8%
Shenzhen Agricultural Products 000061.SZChina$1.52B-22%-22%12%3.0×3.5%+15.6%
China Modern Dairy 1117.HKHong Kong$1.50B+29%+5%-15%2.2×n/an/a

Questions

Who are Curaleaf's main competitors?
Named competitors: Trulieve Cannabis (TRLV), Green Thumb Industries (private or unlisted), Verano Holdings (private or unlisted), Cresco Labs (private or unlisted), TerrAscend (private or unlisted), Glass House Brands (private or unlisted). The cockpit's measured peer set (industry) also includes Lien Hwa Industrial (1229.TW), Guangxi Yuegui Guangye (000833.SZ), B.F (BFG.MI), Trulieve Cannabis (TRLV), Fuji Oil (2607.T), BioMar Group A/S (BIOMAR.CO).
Is Curaleaf expensive compared with its peers?
On ev / sales it trades at 2.4× against a peer median of 1.5×, 7th most expensive of 21 in its peer set.
How has Curaleaf stock performed?
Over six months to 18 Nov 2026 the shares returned -17.0% against 0.0% for the median peer; over one year +33.7%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.